ArticleInternal medicine (Tokyo, Japan)2024

Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series.

Shuhei Hosomi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.